Answers are grounded in this paper and cite their sources.
Chronic gastrointestinal diseases, including inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS), impose a growing global burden. Their relapsing-remitting nature and variable clinical course challenge the paradigm of long-term continuous therapy, which is associated with adverse effects, poor adherence, and high costs. While dynamic precision therapy (DPT) has emerged as an intuitive solution, its conventional definition-symptom-driven, intermittent drug use-is too narrow and fails to harness the full potential of precision medicine. As a narrative review and perspective article, this paper proposes a paradigm shift by introducing a novel, multidimensional framework for DPT that integrates four synergistic dimensions: symptom-guided relief for acute episodes, disease subtype-guided baseline therapy, pathophysiology-guided dynamic adjustments using biomarkers and smart technologies, and individual patient context-guided shared decision-making. Applying this framework to IBD, GERD, and IBS, we demonstrate how it transforms precision treatment from a simple dosing strategy into a comprehensive platform for precision management. We review cutting-edge tools enabling this vision, from 24-hour pH-impedance monitoring and therapeutic drug monitoring to smart drug delivery systems like MMP-responsive hydrogels. This framework provides a practical guide for transitioning from empirical methods to mechanism-based, patient-centered care, presenting a forward-looking model that could transform future treatment approaches in gastroenterology.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: